EnvisionPharmacies’ President Bruce Scott Named to Prestigious Healthcare Industry Board
September 07 2017 - 9:12AM
Business Wire
Bruce Scott brings 37 years of pharmacy
management experience to URAC Board
Collaboration among industry leaders will help
drive new ways to control specialty medication costs and ensure
quality care across thousands of new specialty pharmacies
Bruce Scott, R.Ph., president of EnvisionPharmacies, a division
of EnvisionRxOptions, a wholly owned subsidiary of Rite Aid
Corporation, was recently elected to the URAC board of directors.
As a third-party accreditation organization with a mission of
promoting continuous improvement in the quality and efficiency of
healthcare management, URAC was seeking a board member who could
provide sound advice regarding the growing specialty medication
market. Scott’s extensive background and experience with specialty
pharmacy and benefit management will help this accrediting
organization address this critical issue.
“Given Bruce’s knowledge and extensive experience he brings to
our organization, it’s no surprise that URAC would select him for
this role,” stated Frank Sheehy, CEO of EnvisionRxOptions. “Under
his leadership, EnvisionPharmacies has secured multiple URAC
accreditations, including Specialty Pharmacy, and has been
nationally recognized for award-winning condition management and
industry-leading patient satisfaction. Bruce understands the
critical need to integrate specialty pharmacy in order to optimize
overall patient and payer outcomes.”
With almost 40 years of pharmacy experience, Scott has acquired
in-depth knowledge of the ever-growing specialty medication market.
For the past three years, he has served as president of
EnvisionPharmacies, overseeing the company’s mail order, specialty
and compounding pharmacy operations. Previously, he has held
executive roles with pharmaceutical manufacturers on the marketing
and distribution channels of specialty medication; pharmacy benefit
managers (PBMs) and payers regarding benefit design, contracting
and utilization management; and pharmacies to administer the
benefit design and manage the care process.
“Specialty medications are making great strides in addressing
complex, high-cost conditions, such as rheumatoid arthritis,
multiple sclerosis, hepatitis C and others,” Scott said. “The
diseases these expensive medications are used to treat often
manifest differently from patient to patient, demanding more
individualized attention and a much stronger knowledge of not just
pharmacy, but things like site of care and benefit coverage. The
industry hasn’t really seen this before.”
Specialty medication spend has doubled in the past five years
and is expected to account for 42% of the pharmacy industry’s
revenue by 20211. With nearly half of all Americans suffering from
at least one chronic condition—many of which require specialty
medications for treatment—managing cost and care is paramount2. As
more specialty medications enter the market, it is important to
have a governing body like URAC to help define best practices for
individualized care to better manage the condition and costs for
this burgeoning industry.
As an independent leader in promoting healthcare quality through
accreditation, certification, education, and measurement, URAC
regularly reviews and revises their standards and measures
reporting requirements to consistently align with market needs,
government regulations and industry trends. With the development of
new, complex and costly drugs, pharmacy services has never played
such an important role in the delivery of care as it does today,
particularly specialty pharmacy services.
“There is more to managing specialty drugs than simply
dispensing a medication,” Scott commented. “Specialty pharmacy
patients require a high-touch experience with additional care,
comprehensive education and strong support to achieve optimal
outcomes. That is why, with the increasing number of pharmacies
claiming the title of ‘specialty pharmacy,’ it is important to have
the rigorous credentialing processes that URAC provides. URAC
accreditation demonstrates a willingness to stand behind
performance.”
Scott will serve a three-year term on the URAC board, providing
expertise to address the challenges of the industry, including
specialty medication cost and care management. “URAC is
consistently seeking to advance quality in this industry,” Scott
commented. “I am honored to be a member of their board and
contribute to the future of healthcare performance.”
About EnvisionRxOptions
A wholly owned subsidiary of Rite Aid, EnvisionRxOptions is a
healthcare company with a visibly different approach to pharmacy
benefits. Its pharmacy division, EnvisionPharmacies, is URAC
accredited for Specialty Pharmacy and Mail Order, and safely
dispenses medications through convenient home delivery of
traditional maintenance medications, specialty drugs and customized
compounds. EnvisionPharmacies’ award-winning pharmacy care model
focuses on the unique needs of patients with chronic, complex
conditions, better coordinating care and improving outcomes for
patients, providers, and payers. For more information, visit
envisionpharmacies.com and envisionrx.com.
1 Fein, A. J. (2017). The 2017 Economic Report on U.S.
Pharmacies and Pharmacy Benefit Managers. Philadelphia: Drug
Channels Institute.2 Centers for Disease Control and Prevention,
Chronic Disease Overview,
https://www.cdc.gov/chronicdisease/overview/index.htm
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907005901/en/
EnvisionRxOptionsBobby Creek,
813-690-8503bcreek@envisionrx.com
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Apr 2023 to Apr 2024